Methods and compositions for increasing protein expression and/or treating a haploinsufficiency disorder
A tRNA that hybridizes to a non-optimal codon can be used to increase expression in a mammalian cell of a gene product encoded by a gene containing the non-optimal codon or to treat a haploinsufficiency disorder in a subject having a haploinsufficient gene containing the non-optimal codon.
1. A method of increasing expression in a mammalian cell of a gene product encoded by a gene containing a first, second, and third non-optimal codon, the method comprising introducing into the cell an effective amount of a first, second, and third exogenous transfer RNA (tRNA) that each (i) comprises an anticodon that hybridizes to the first, second, and third non-optimal codon, respectively, and (ii) is capable of being aminoacylated with an amino acid, wherein introduction of the first, second, and third exogenous tRNAs into the cell increases the expression of the gene product relative to a similar cell lacking the first, second, and third exogenous tRNAs, and wherein the first, second, and/or third non-optimal codon is selected from ATA, GTA, and AGA.
2. The method of claim 1 , wherein the cell is a human cell.
3. The method of claim 1 , wherein the gene is selected from AGGF1, ARHGAP31, BMPR2, CHD7, COL2A1, COL3A1, CTLA4, CTNNB1, DLL4, EHMT1, ELN, ENG, FAS, FBN1, FOXG1, GATA3, GLI3, GRN, IRF6, JAG1, KCNQ4, LMX1B, MBD5, MED13L, MITF, MNX1, MYCN, NFIA, NFIX, NOTCH1, NSD1, PAX3, PHIP, PRKAR1A, RAI1, RBPJ, RPS14, RUNX2, SALL4, SCN1A, SETBP1, SHANK3, SHH, SHOX, SLC2A1/GLUT1, SOX10, SYNGAP1, TBX1, TBX3, TBX5, TCF4, TCOF1, TGIF1, TNXB, TRPS1, WT1, and ZIC2.
4. The method of claim 1 , wherein the gene is SCN1A.
5. The method of claim 1 , wherein the first, second, and/or third tRNA is selected from a tRNA comprising the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3.
6. A method of increasing expression in a mammalian cell of a gene product encoded by a gene containing a first, second, and third non-optimal codon, comprising introducing into the cell an effective amount of a combination of three expression vectors, wherein upon administration to the mammalian cell, each expression vector is capable of expressing an exogenous tRNA that (i) comprises an anticodon that hybridizes to the first, second, or third non-optimal codon, respectively, and (ii) is capable of being aminoacylated with an amino acid, wherein expression of the first, second, and third exogenous tRNAs in the cell increases the expression of the gene product relative to a similar cell lacking the first, second, and third exogenous tRNAs, and wherein the first, second, and/or third non-optimal codon is selected from ATA, GTA, and AGA.
7. The method of claim 6 , wherein the first, second, and/or third expression vectors are the same.
8. The method of claim 6 , wherein the first, second, and/or third expression vector is a viral vector.
9. The method of claim 8 , wherein the first, second, and/or third expression vector is an adeno-associated virus (AAV) vector.
10. The method of claim 6 , wherein the first, second, and/or third expression vector comprises a nucleotide sequence selected from SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.